Ampio Pharmaceuticals Incorporated (NYSEMKT:AMPE) Shorts Decreased by 2.66% After Short Covering


The stock of Ampio Pharmaceuticals Incorporated (NYSEMKT:AMPE) registered a decrease of 2.66% in short interest. AMPE’s total short interest was 5.56M shares in September as published by FINRA. Its down 2.66% from 5.71M shares, reported previously. With 420,800 shares average volume, it will take short sellers 13 days to cover their AMPE’s short positions. The short interest to Ampio Pharmaceuticals Incorporated’s float is 14.57%. The stock decreased 4.42% or $0.04 during the last trading session, hitting $0.86. About 147,770 shares traded hands. Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has declined 56.73% since February 8, 2016 and is downtrending. It has underperformed by 73.22% the S&P500.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $50.72 million. The Firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. It currently has negative earnings. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

The institutional sentiment increased to 2.12 in Q2 2016. Its up 0.98, from 1.14 in 2016Q1. The ratio increased, as 6 funds sold all Ampio Pharmaceuticals Inc shares owned while 11 reduced positions. 16 funds bought stakes while 20 increased positions. They now own 11.72 million shares or 32.69% more from 8.83 million shares in 2016Q1.

Knoll Capital Management Lp holds 1.35% of its portfolio in Ampio Pharmaceuticals Inc for 3.24 million shares. Noven Financial Group Inc. owns 252,667 shares or 0.22% of their US portfolio. Moreover, Fort Point Capital Partners Llc has 0.08% invested in the company for 121,400 shares. The Ohio-based Camelot Portfolios Llc has invested 0.03% in the stock. Ghp Investment Advisors Inc., a Colorado-based fund reported 90,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply